Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Well Corp (AMWL) vs Appian Corp (APPN) Price & Performance

American Well CorpTrade
Appian CorpTrade

Price performance (Past 24H)

Key statistics

American Well Corp vs Appian Corp — how do they compare? American Well Corp trades at $13.01 (market cap $230.98M), while Appian Corp trades at $35.5 (market cap $2.55B). The key difference: Appian Corp is far larger — about 11× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.

AMWLAPPN
Market Cap
$230.98M$2.55B
Sector
HealthTechnology
52-Week High
$13.58$45.64
52-Week Low
$3.78$18.72
Enterprise Value
$38.01M$2.68B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Well Corp

AMWL (American Well Corporation) trades at $13.52, up 4.56% today, with a bullish technical signal from moving averages. The company shows improving financial trends with narrowing losses—net income margin improved from -97.57% in 2022 to -35.75% in 2026—and positive earnings beats in recent quarters. Recent news highlights include a Defense Health Agency partnership intent and leadership changes at Amazon's healthcare unit involving an Amwell co-founder. Operating cash flow losses have decreased significantly from -$192M in 2022 to -$26M projected for 2026.

Outlook: AMWL's path to operating breakeven by Q4 2026 and reduced cash burn present a turnaround opportunity, but persistent revenue declines and negative margins pose risks. Analyst sentiment is mixed with 33% buy ratings. The stock's valuation at P/S of 1.02 appears reasonable if growth resumes, but execution on profitability targets is critical for sustained upside.

Appian Corp

Appian (APPN) surged 13.91% to $34.64 following strong Q2 2026 earnings that exceeded expectations, with cloud subscription revenue growing 23% year-over-year. The stock trades near its pivot point of $34 with bullish technical signals from moving averages, though RSI levels suggest potential overbought conditions. Revenue growth has accelerated from $617M in 2024 to $727M in 2025, with the company achieving its first profitable year with $1.23M net income after several years of losses.

Appian demonstrates improving fundamentals with consistent revenue growth and recent profitability, though negative equity and high debt levels present risks. Analyst sentiment is mixed with 31.58% buy ratings but a consensus price target of $32.50 below current levels. The AI-driven workflow platform shows strong enterprise adoption, but investors should weigh growth potential against valuation concerns and competitive pressures in the low-code automation space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Well Corp

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.

Read more on AMWL

About Appian Corp

Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.

Read more on APPN